Medicines optimisation: key therapeutic topics consultation for the 2019 update
 

As part of the NICE Medicines and Technologies Programme's work to support NHS England’s Medicines Value Programme, we are in the process of updating the Medicines optimisation: key therapeutic topics document. The final document will be published in February 2019.

We are now consulting on the topics to be included in the February 2019 update. You can view an outline of the proposed changes to the topics that will be included in the update on the NICE website. We would be pleased to receive any comments on these proposals by 5pm on 1 August 2018 by emailing them to adminteam@nice.org.uk.

Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy)

Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) is the latest topic to be covered as part of our service to provide high quality medicines and prescribing information to the NHS and patients in England.

Evidence summaries provide a summary of the best available evidence for selected medicines that are considered to be of significance to the NHS. These medicines include new medicines, existing medicines with new indications or formulations, off-label use of licensed medicines and unlicensed medicines. The summaries aim to support decision-making, nationally within NHS England and locally, for example within a clinical commissioning group, an NHS trust, or across a local health economy. The evidence summaries do not include recommendations and do not constitute formal NICE guidance.

Information about the process used to develop them and those evidence summaries that are currently being developed is available on the NICE website.